Sangamo Therapeutics Company

Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Technology: Biotechnology, Genetics, Pharmaceutical, Therapeutics
Industry: End-to-end Drug Development
Headquarters: Richmond, California, United States
Founded Date: 1995-01-01
Employees Number: 251-500
Funding Status: IPO
Acquisitions Number: 2
Investors Number: 2
Total Funding: 93200000
Estimated Revenue: $10M to $50M
Last Funding Date: 2018-04-27
Last Funding Type: Grant

Visit Website
info@sangamo.com
https://twitter.com/sangamotx
Register and Claim Ownership